Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Immunovia AB ( (SE:IMMNOV) ) has issued an update.
Immunovia has announced that its analytical validation study of PancreaSure, a blood-based test for early detection of pancreatic cancer, has been published in the peer-reviewed medical journal Diagnostics. The study demonstrated strong precision, sensitivity, stability and robustness across more than 23 performance attributes under Clinical and Laboratory Standards Institute guidelines, reinforcing confidence in PancreaSure’s reliability for early-stage pancreatic cancer detection and strengthening Immunovia’s scientific and commercial positioning in the high-risk screening market. The work has already received industry recognition via a 2025 Distinguished Abstract Award at the ADLM Annual Meeting, which further underpins the test’s credibility with clinicians and laboratories and may support broader adoption as stakeholders seek more effective tools for early pancreatic cancer surveillance.
More about Immunovia AB
Immunovia AB is a Swedish diagnostics company focused on improving survival rates for pancreatic cancer patients through early detection. The company develops and commercializes simple blood-based tests that detect proteins and antibodies associated with pancreatic cancer, targeting individuals at increased risk, particularly in the U.S. market, where it estimates 1.8 million high‑risk individuals could benefit from annual surveillance testing. Immunovia’s shares are listed on Nasdaq Stockholm.
YTD Price Performance: -48.11%
Average Trading Volume: 6,546,776
Technical Sentiment Signal: Sell
Current Market Cap: SEK141.1M
Find detailed analytics on IMMNOV stock on TipRanks’ Stock Analysis page.